← Back to Screener
PepGen Inc. Common Stock (PEPG)
Price$1.41
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-86.03%
Price vs S&P 500 (4W)-19.88%
VGM Score28.11
Market Capitalization$97.53M
All Metrics
Book Value / Share (Quarterly)$1.94
P/TBV (Annual)0.59x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.12
Price vs S&P 500 (YTD)-86.50%
EPS (TTM)$-1.75
10-Day Avg Trading Volume0.58M
EPS Excl Extra (TTM)$-1.75
EPS (Annual)$-2.12
ROI (Annual)-60.81%
Cash / Share (Quarterly)$1.91
ROA (Last FY)-51.55%
EBITD / Share (TTM)$-1.56
ROE (5Y Avg)-53.63%
Cash Flow / Share (Annual)$-1.19
P/B Ratio0.73x
P/B Ratio (Quarterly)0.91x
Net Income / Employee (Annual)$-1,601,000
ROA (TTM)-49.62%
EPS Incl Extra (Annual)$-2.12
Current Ratio (Annual)11.94x
Quick Ratio (Quarterly)14.76x
3-Month Avg Trading Volume1.20M
52-Week Price Return-0.70%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$5.29
52-Week High$7.80
EPS Excl Extra (Annual)$-2.12
CapEx CAGR (5Y)92.45%
26-Week Price Return-78.11%
Quick Ratio (Annual)11.74x
13-Week Price Return-74.39%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)14.98x
Enterprise Value$55.38M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$2.16
3-Month Return Std Dev136.80%
Net Income / Employee (TTM)$-1,378,900
ROE (Last FY)-60.81%
EPS Basic Excl Extra (Annual)$-2.12
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.75
ROI (TTM)-59.89%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$7.58
Price vs S&P 500 (52W)-25.07%
Year-to-Date Return-78.34%
5-Day Price Return-4.08%
EPS Normalized (Annual)$-2.12
ROA (5Y Avg)-43.39%
Month-to-Date Return-6.00%
Cash Flow / Share (TTM)$-3.07
EBITD / Share (Annual)$-2.18
ROI (5Y Avg)-53.63%
EPS Basic Excl Extra (TTM)$-1.75
P/TBV (Quarterly)0.85x
P/B Ratio (Annual)3.04x
Book Value / Share (Annual)$2.14
Price vs S&P 500 (13W)-82.64%
Beta1.93x
Revenue / Share (TTM)$0.00
ROE (TTM)-59.89%
52-Week Low$1.01
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.26est. -0.32
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.25
4.31
4.31
4.31
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PEPGPepGen Inc. Common Stock | — | — | D | $1.41 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
PepGen is a clinical-stage biotechnology company developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases using its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. The EDO platform improves tissue penetration and cellular uptake of therapeutic oligonucleotides across multiple target tissues, including skeletal and cardiac muscle as well as the central nervous system, as demonstrated in preclinical studies. The company has multiple EDO-based candidates in development.